STAR2026-07-03STAR2026-07-032026-07-03iso4217:INRxbrli:pure532531Strides Pharma Science LimitedSTARNOTLISTEDINE939A01011Updatefalse2026-07-0307:44:002026-06-272026-06-272026-07-03Sale or disposal of unit(s)/division(s)/subsidiaryPress Release issued by the Company on June 27, 2026 titled “Strides Partners with Ascent Capital to Unlock Value in Pivot Path” and the disclosure made under Regulation 30 of SEBI Listing Regulations.Transaction CompletedWith reference to the above, we wish to inform you that the transaction pertaining to Strides’ partnership with Ascent Capital for unlocking value in Pivot Path has been successfully completed. As previously disclosed, the transaction involved sale of Strides’ majority stake in Pivot Path to a consortium led by Ascent Capital, together with co-investor Vintage Classic, for an aggregate consideration of approximately ₹1,000 million. Pursuant to completion of the transaction, the Company has received ₹750 million, with the balance consideration of ₹250 million being payable on the first anniversary of the closing date, in accordance with the agreed transaction terms. Consequent to the completion of the transaction, Pivot Path has ceased to be a Wholly Owned Subsidiary of the Company with effect from July 1, 2026 and shall henceforth be classified as an Associate Company. Kindly take the above information on record.7500000002026-07-030.5